Denosumab may reduce radiographic progression, prevent new erosive joints in hand OA
Click Here to Manage Email Alerts
Key takeaways:
- The denosumab and placebo groups had an estimated difference of 8.9 in the Ghent University Scoring System at 24 weeks.
- The placebo group had a greater development of new erosive joints at 48 weeks.
Published results showed use of denosumab may reduce radiographic progression and prevent new erosive joints among patients with erosive hand osteoarthritis.
Researchers randomly assigned patients with erosive hand OA to receive either 60 mg of denosumab every 3 months (n = 51) or a placebo (n = 49) for 48 weeks. Researchers considered change in the total Ghent University Scoring System score at week 24, where positive changes correspond to remodeling, as the primary endpoint. Secondary endpoints included change in the Ghent University Scoring System score and the number of new erosive joints by the anatomical phase scoring system at week 48.
At week 24, results showed patients in the denosumab group had a baseline adjusted mean Ghent University Scoring System score of 162.2 vs. 153.3 in the placebo group, with an estimated difference of 8.9 between groups. Researchers confirmed this effect at week 48, with an estimated difference of 14.3 between groups.
Researchers found the placebo group had a statistically greater development of new erosive joints at week 48 compared with the denosumab group. The placebo group also experienced more adverse events than the denosumab group (125 events vs. 97 events).
At week 48, researchers found 87 patients entered the extension phase of the study, which ended at week 96. Of these patients, 44 originally received denosumab and 43 originally received placebo.
While both groups experienced an increase in total Ghent University Scoring System score compared with baseline, researchers found a greater increase in the former placebo group vs. the initial denosumab group. Results showed a statistically significant decrease in pain levels at week 96 among patients from the original denosumab group compared with baseline and patients from the initial placebo group.
“This study introduces new promising treatment possibilities for patients suffering from a disease, such as erosive hand OA, with high unmet needs,” the researchers wrote in the study.
Collapse
Read more about
Click Here to Manage Email Alerts